Indication: Cabozantinib (INN) is used to treat various cancers, including renal cell carcinoma (RCC), advanced hepatocellular carcinoma (HCC), and medullary thyroid cancer (MTC) in patients with locally advanced or metastatic disease.

Pharmacology: Cabozantinib inhibits specific tyrosine kinases involved in tumor growth and angiogenesis, such as MET, VEGFRs, and RET. By blocking these pathways, cabozantinib suppresses tumor growth and impacts the tumor microenvironment.

Dosage and Administration: The typical starting dose for RCC is 60 mg orally once daily, with adjustments based on individual patient factors and tolerability.

Interaction: Cabozantinib may interact with various medications, particularly strong CYP3A4 inhibitors and inducers. Patients should inform healthcare providers of all medications to avoid potential interactions.

Side Effects: Common side effects include fatigue, diarrhea, decreased appetite, nausea, hypertension, hand-foot syndrome, and weight loss. Serious adverse effects may include perforations, fistulas, hemorrhage, thromboembolism, hepatotoxicity, and osteonecrosis of the jaw.

Precautions and Warnings: Patients should be monitored for hypertension, proteinuria, hemorrhage, and perforations or fistulas. Regular liver function tests are advised, and patients should avoid activities that increase bleeding risk.

Overdose Effects: In the event of an overdose, supportive measures are recommended, as there is no specific antidote for cabozantinib. Treatment should focus on managing symptoms and providing supportive care.